low dose BIBF1120 once daily; low dose BIBF 1120 twice daily; intermediate dose BIBF 1120 twice daily; high dose BIBF 1120 twice daily; placebo
Проводит Boehringer Ingelheim
Страница компанииA 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00514683/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 40 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 432 чел. во всех странах исследования.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 18 · невключение: 24
Критерии включения
- Patient >40 years
- Written informed consent signed prior to entry into the study
- IPF diagnosed (according to ATS / ERS criteria) less than 5 years prior to screening visit.
- HRCT within 12 months of randomisation and biopsy (the latter if needed to fulfil ATS/ERS criteria) centrally reviewed and consistent with diagnosis.
- FVC>50 % of predicted value
- Predicted normal values will be calculated according to ESCS (R94-1408):
- Males :
- FVC predicted (L) = 5.76 x height (meters)- 0.026 x age (years) -4.34
- Females :
- FVC predicted (L) = 4.43 x height (meters)- 0.026 x age (years) -2.89
- Single breath DLCO (corrected for Hb) 30 - 79% inclusive of predicted .
- Different sites may use different prediction formulas, based on the method used to measure DLco. In any case, the method used must be in compliance with the ATS/ERS guideline on DLCO measurements (R06-2002), and the prediction formula appropriate for that method. Raw data (gas mixture, equation used for prediction of normal, further adjustments made if so) must be traced.
- Adjustment for haemoglobin (R06-2002):
- Males :
- DLCO predicted for Hb = DLCO predicted x (1.7Hb/\[10.22+Hb\])
- Females :
- DLCO predicted for Hb = DLCO predicted x (1.7Hb/\[9.38+Hb\]) where Hb is expressed in g/dL-1
- PaO2 >= 55 mmHg (sea level to 1500 m) or 50 mmHg (above 1500 m) room air
Критерии невключения
- AST, ALT > 1.5 x ULN ;
- Bilirubin > 1.5 x ULN
- Relevant airways obstruction
- Continuous oxygen supplementation at randomisation (defined as > 15 hours supplemental oxygen per day).
- Active infection at screening or randomisation.
- Neutrophils < 1500 / mm3
- International normalised ratio (INR) > 1.5 and/or Partial thromboplastin time (PTT) > 1.5 x ULN ;
- Platelets < 100 000 /mL
- Haemoglobin < 9.0 g/dL
- In the opinion of the Investigator, patient is likely to have lung transplantation during study
- Life expectancy for disease other than IPF < 2.5 years (Investigator assessment).
- Other disease that may interfere with testing procedures or in judgement of Investigator may interfere with trial participation or may put the patient at risk when participating to this trial.
- Myocardial infarction during the previous 6 months
- Unstable angina during the previous month
- Other investigational therapy received within 8 weeks prior to screening visit.
- Pregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of birth control for at least one month prior to enrolment.
- Sexually active males not committing to using condoms during the course of the study (except if their partner is not of childbearing potential).
- Known or suspected active alcohol or drug abuse.
- Bleeding risk : Known inherited predisposition to bleeding, patients who require full-dose anticoagulation, Patients who require full-dose antiplatelet therapy, History of hemorrhagic CNS event within 12 months prior to screening , Any of the following within 3 months prior to screening : Gross / frank haemoptysis or haematuria, Active gastro-intestinal bleeding or ulcers, Major injury or surgery
- Thrombotic risk
- Surgical procedures planned to occur during trial period.
- Coagulopathy
- Uncontrolled systemic arterial hypertension
- known hypersensitivity to lactose or any component of the study medication
Источник: ClinicalTrials.gov, NCT00514683 · запись обновлена в реестре 6 января 2015.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 36
- Rate of Decline in FVC — Baseline until 52 weeks
Цель исследования
The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis.
The primary objective of this study is to demonstrate whether at least one dose strategy is superior to placebo in patients with IPF, in modifying the rate of decline of Forced Vital Capacity (FVC).
As a secondary objective, additional parameters will be assessed in order to differentiate between dose strategies on the basis of safety and efficacy
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00514683 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.